AR056418A1 - Derivados de bencimidazol como 5-ht6, 5-ht2a, metodo para la obtencion del compuesto y el uso para la fabricacion de un mediicamento - Google Patents

Derivados de bencimidazol como 5-ht6, 5-ht2a, metodo para la obtencion del compuesto y el uso para la fabricacion de un mediicamento

Info

Publication number
AR056418A1
AR056418A1 ARP060102971A ARP060102971A AR056418A1 AR 056418 A1 AR056418 A1 AR 056418A1 AR P060102971 A ARP060102971 A AR P060102971A AR P060102971 A ARP060102971 A AR P060102971A AR 056418 A1 AR056418 A1 AR 056418A1
Authority
AR
Argentina
Prior art keywords
alkyl
hydrogen
optionally substituted
independently
attached
Prior art date
Application number
ARP060102971A
Other languages
English (en)
Inventor
Timothy D Owens
Steven Sethofer
Keith Adrian Murray Walker
Shu-Hai Zhao
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37054633&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR056418(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR056418A1 publication Critical patent/AR056418A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/38—Oxygen atoms in positions 2 and 3, e.g. isatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Abstract

Compuestos derivados de bencimidazol, un método para la obtencion de los mismos, composiciones que contienen dichos compuestos y métodos para el uso de los compuestos de la formula (1) para preparar un medicamento. Los compuestos son utiles para tratar enfermedades del SNC como el Parkinson y la ansiedad. Reivindicacion 1: Un compuesto de la formula (1), o una sal farmacéuticamente aceptable de los mismos, en la que: m es un numero 0 a 3; n es 1 o 2; X es: -NRa-; -O-; -S-; -CRbRc-; o -C(O)- ; en los que: Ra es hidrogeno o alquilo; Rb es hidrogeno, fluor o alquilo; Rc es hidrogeno, fluor, alquilo, hidroxi; o alcoxi; o Rb y Rc juntos forman oxo; o Rb y Rc junto con el átomo de carbono al que están unidos pueden formar un anillo de tres a seis eslabones opcionalmente sustituido que contiene opcionalmente un heteroátomo elegido entre O, N y S; Ar es: arilo opcionalmente sustituido; o heteroarilo opcionalmente sustituido; R1 es un grupo de la formula (2); p es un numero de 1 a 4; Y es: -O-; -NRd-; o -CReRf-; en los que Rd, Re y Rf con independencia entre sí son hidrogeno o alquilo; cada R2 con independencia de su aparicion es: halogeno; alquilo; haloalquilo; haloalcoxi; alcoxi; heteroalquilo; ciano; -(CH2)q-S(O)r-Rg; -(CH2)q-C(=O)- NRhRi; -(CH2)q-SO2-NRhRi; -(CH2)q-N(Rj)-C(=O)-Rk, o -(CH2)q-C(=O)-Rk; en los que: q es 0 o 1; r es un numero de 0 a 2; y Rg, Rh, Ri y Rj con independencia entre sí son hidrogeno o alquilo, y Rk es hidrogeno, alquilo, alcoxi o hidroxi; R3 y R4 con independencia entre sí son hidrogeno o alquilo; R5 y R6 con independencia entre sí son hidrogeno o alquilo; y R7 y R8 con independencia entre sí son hidrogeno o alquilo; o R7 y R8 junto con el átomo de nitrogeno al que están unidos pueden formar un anillo de cuatro a siete eslabones opcionalmente sustituido que contiene opcionalmente un heteroátomo adicional elegido entre O, N y S; o uno de R7 y R8 y uno de R5 y R6 unto con los átomos a los que están unidos pueden formar un anillo de cuatro a siete eslabones opcionalmente sustituido que contiene opcionalmente un heteroátomo adicional elegido entre O, N y S; o uno de R7 y R8 junto con Rd y los átomos a los que están unidos pueden formar un anillo de cuatro a siete eslabones opcionalmente sustituido que contiene opcionalmente un heteroátomo adicional elegido entre O, N y S; o uno de R7 y R8 y uno de Re y Rf junto con los átomos a los que están unidos pueden formar un anillo de cuatro a siete eslabones que contiene opcionalmente un heteroátomo adicional elegido entre O, N y S.
ARP060102971A 2005-07-13 2006-07-11 Derivados de bencimidazol como 5-ht6, 5-ht2a, metodo para la obtencion del compuesto y el uso para la fabricacion de un mediicamento AR056418A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69943505P 2005-07-13 2005-07-13

Publications (1)

Publication Number Publication Date
AR056418A1 true AR056418A1 (es) 2007-10-10

Family

ID=37054633

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060102971A AR056418A1 (es) 2005-07-13 2006-07-11 Derivados de bencimidazol como 5-ht6, 5-ht2a, metodo para la obtencion del compuesto y el uso para la fabricacion de un mediicamento

Country Status (16)

Country Link
US (1) US7582760B2 (es)
EP (1) EP1904483A1 (es)
JP (1) JP2009501184A (es)
KR (1) KR100983752B1 (es)
CN (1) CN101263136A (es)
AR (1) AR056418A1 (es)
AU (1) AU2006268713A1 (es)
BR (1) BRPI0613430A2 (es)
CA (1) CA2615007A1 (es)
IL (1) IL188486A0 (es)
MX (1) MX2008000411A (es)
NO (1) NO20080110L (es)
RU (1) RU2415138C2 (es)
TW (1) TW200738697A (es)
WO (1) WO2007006677A1 (es)
ZA (1) ZA200800213B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005026543D1 (de) * 2004-09-30 2011-04-07 Hoffmann La Roche Zusammensetzungen und verfahren zur behandlung kognitiver störungen
WO2008116833A1 (en) 2007-03-23 2008-10-02 Abbott Gmbh & Co. Kg Azetidin compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor
CL2008000838A1 (es) 2007-03-23 2008-10-10 Neuraxon Inc Compuestos derivados de quinolina y tetrahidroquinolina, con actividad inhibidora nos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un dolor de cabeza tal como migrana, dolor cronico, desordenes del sistema nervios
CN102153538B (zh) * 2010-02-11 2013-12-11 山东轩竹医药科技有限公司 苯并环衍生物
AU2015286049B2 (en) 2014-07-08 2018-03-01 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic derivatives and pharmaceutical applications thereof
AU2016348493B2 (en) 2015-11-06 2021-02-25 F. Hoffmann-La Roche Ag Indolin-2-one derivatives
CN107118161B (zh) * 2017-05-05 2019-12-31 湖北工业大学 2-正丙基-4-甲基苯并咪唑-6-羧酸的合成方法
EP3530651A1 (en) * 2018-02-21 2019-08-28 Adamed sp. z o.o. Indole and benzimidazole derivatives as dual 5-ht2a and 5-ht6 receptor antagonists

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2510111A1 (fr) * 1981-07-24 1983-01-28 Roussel Uclaf Nouveaux derives du piperidin-3-yl indole, leurs sels, leur procede de preparation, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant
FR2510112A1 (fr) * 1981-07-24 1983-01-28 Roussel Uclaf Nouveaux derives du 2-oxo-pyrid-3-yl ou piperidin-3-yl indole, leurs sels, procede de preparation, application a titre de medicaments et compositions les renfermant
FR2621586B1 (fr) 1987-10-08 1990-02-02 Roussel Uclaf Nouveaux derives de l'azapirodecane, leur procede de preparation et leur application comme medicaments
TW203049B (es) 1990-04-13 1993-04-01 Yamanouchi Pharma Co Ltd
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
FR2667068B1 (fr) * 1990-09-26 1994-09-09 Adir Nouvelles amines alkyl heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5834587A (en) * 1996-10-08 1998-11-10 Smithkline Beecham Corporation G-protein coupled receptor, HLTEX 11
AU2074699A (en) 1998-01-26 1999-08-09 Yamanouchi Pharmaceutical Co., Ltd. Novel benzene-fused heterocyclic derivatives or salts thereof
US6310066B1 (en) * 1998-04-29 2001-10-30 American Home Products Corp. Antipsychotic indolyl derivatives
JP2002513001A (ja) 1998-04-29 2002-05-08 アメリカン・ホーム・プロダクツ・コーポレイション 抗精神病性のインドリル誘導体
EP1263754A1 (en) 2000-02-01 2002-12-11 Millennium Pharmaceuticals, Inc. INDALONE AND BENZIMIDAZOLONE INHIBITORS OF FACTOR Xa
WO2001072708A2 (en) 2000-03-24 2001-10-04 Cor Therapeutics, Inc. OXINDOLE INHIBITORS OF FACTOR Xa
WO2001081343A2 (en) 2000-04-21 2001-11-01 Pharmacia & Upjohn Company Compounds for treating fibromyalgia and chronic fatigue syndrome
AR033520A1 (es) 2000-04-27 2003-12-26 Upjohn Co (5r)-(metilamino) -5,6-dihidro-4h-imidazo[4,5,1-ij] quinolin-2(1h)-tiona
US6440096B1 (en) * 2000-07-14 2002-08-27 Becton, Dickinson And Co. Microdevice and method of manufacturing a microdevice
AR031152A1 (es) 2000-10-31 2003-09-10 Upjohn Co Tratamientos nuevos para el sindrome de piernas inquietas
US20060167046A1 (en) 2002-09-18 2006-07-27 Eli Lilly And Company Patent Division Histamine h3 receptor antagonists, preparation and therapeutic uses
KR20050057671A (ko) 2002-10-25 2005-06-16 파마시아 앤드 업존 캄파니 엘엘씨 신경보호제로서의 헤테로시클릭 아민-타입 화합물의 용도
PL377770A1 (pl) 2002-11-08 2006-02-20 F. Hoffmann-La Roche Ag Podstawione benzoksazynony i ich zastosowanie
CA2532071A1 (en) * 2003-07-23 2005-02-03 Wyeth Sulfonyldihydro- benzimidazolone compounds as 5-hydroxytryptamine-6 ligands
MXPA06000700A (es) * 2003-07-23 2006-04-11 Wyeth Corp Compuestos de sulfonildihidroimidazopiridinona como ligandos de 5-hidroxitriptamina-6.
JP4533391B2 (ja) * 2004-01-16 2010-09-01 エフ．ホフマン−ラ ロシュ アーゲー 中枢神経系疾患の処置のための５−ヒドロキシトリプタミンレセプター（５−ｈｔ）のモジュレーターとしての、１−ベンジル−５−ピペラジン−１−イル−３，４−ジヒドロ−１ｈ−キナゾリン−２−オン誘導体、ならびにそれぞれの１ｈ−ベンゾ（１，２，６）チアジアジン−２，２−ジオキシドおよび１，４−ジヒドロベンゾ（ｄ）（１，３）オキサジン−２−オン誘導体
DE602005026543D1 (de) * 2004-09-30 2011-04-07 Hoffmann La Roche Zusammensetzungen und verfahren zur behandlung kognitiver störungen
JP2008524246A (ja) * 2004-12-16 2008-07-10 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤

Also Published As

Publication number Publication date
ZA200800213B (en) 2008-12-31
TW200738697A (en) 2007-10-16
JP2009501184A (ja) 2009-01-15
KR100983752B1 (ko) 2010-09-24
BRPI0613430A2 (pt) 2011-01-11
RU2008100081A (ru) 2009-08-20
AU2006268713A1 (en) 2007-01-18
CN101263136A (zh) 2008-09-10
US7582760B2 (en) 2009-09-01
MX2008000411A (es) 2008-03-10
EP1904483A1 (en) 2008-04-02
CA2615007A1 (en) 2007-01-18
IL188486A0 (en) 2008-04-13
NO20080110L (no) 2008-04-11
US20070015744A1 (en) 2007-01-18
KR20080019286A (ko) 2008-03-03
RU2415138C2 (ru) 2011-03-27
WO2007006677A1 (en) 2007-01-18

Similar Documents

Publication Publication Date Title
AR056418A1 (es) Derivados de bencimidazol como 5-ht6, 5-ht2a, metodo para la obtencion del compuesto y el uso para la fabricacion de un mediicamento
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
ATE556058T1 (de) 1-(2h)-isochinolonderivat
AR072906A1 (es) Nucleosidos modificados utiles como antivirales
AR057769A1 (es) Pirazolo pirimidinas como inhibidores de map quinasa p38, metodos para utilizarlos y composiciones farmaceuticas
AR035774A1 (es) Derivados benzimidazol y piridilimidazol, un procedimiento para su preparacion, composiciones farmaceuticas y paquetes que los comprenden, el uso de dichos compuestos solos o en combinacion para la manufactura de medicamentos como ligandos para gabaa, y metodo de tratamiento
AR077328A1 (es) Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos
RU2015148006A (ru) Дейтерированные нуклеозидные пролекарства, применимые для лечения hcv
AR060173A1 (es) Derivados de piridina y de pirimidina como antagonistas del mglur2, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de trastornos del snc.
AR088029A1 (es) Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central
AR049346A1 (es) 3-amino-1-arilpropil-indoles como inhibidores de reabsorcion de monoaminas
CO6150145A2 (es) Derivados de aril/heterociclo/cicloalquil/cicloalquil fenil substituidos utiles como agentes inmunosupresores
AR080785A1 (es) Derivados de imidazo[1,2-a]pirimidina ,proceso para prepararlos e intermediarios de dicha sintesis, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de patologias del sistema nervioso central,tales como esquizofrenia y parkinson, entre otros.
AR081649A1 (es) Compuestos heteroarilo nitrogenados
AR048669A1 (es) Derivados biciclicos de bisamida
ECSP034475A (es) Derivados de 4-fenil-piridin como antagonistas del receptor de neuroquinina-1
AR067757A1 (es) Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales.
AR054890A1 (es) Derivados de quinolina como agentes antibacterianos
AR064414A1 (es) Derivados de 1-azoniabiciclo[2, 2, 2]octano y 1-azabiciclo[2, 2, 2]oct-3-ilo, un proceso para su preparacion, una composicion farmaceutica que los comprende, procedimiento de obtencion de la misma, su uso en la elaboracion de un medicamento para el tratamiento de epoc y un producto farmaceutico que
ES2612921T3 (es) Compuestos de difluorolactama como agonistas selectivos del receptor EP4 para su uso en el tratamiento de enfermedades y afecciones mediadas por EP4
NO20080871L (no) N-(Heteroaryl)-1-heteroarylalkyl-1 H-indol-2-karboksamidderivater, fremstilling og terapeutisk anvendelse derav
AR065891A1 (es) Derivados de piridina y pirimidina como antagonistas del mglur2
AR039988A1 (es) Derivados de benzoxazina como moduladores de 5-ht6 y usos de los mismos
PE20061362A1 (es) Derivados de tetrahidronaftalina, procedimientos para su preparacion y su uso como inhibidor de la inflamacion

Legal Events

Date Code Title Description
FA Abandonment or withdrawal